Analysis of voice and speech performance in Parkinson’s disease: a promising tool for the monitoring of disease progression and differential diagnosis

2012 ◽  
Vol 2 (5) ◽  
pp. 535-545 ◽  
Author(s):  
Sabine Skodda
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Differential Diagnosis ◽  
Disease Progression ◽  
Promising Tool ◽  
Speech Performance ◽  
Voice And Speech

scholarly journals Assessment of Hearing Impairment in Parkinson's Disease: Implications for Differential Diagnosis and Disease Progression

2017 ◽  
Vol 07 (06) ◽  
Author(s):  
Roberta Di Mauro ◽  
Giulia Di Lazzaro ◽  
Tommaso Schirinzi ◽  
Federica Martino ◽  
Nicola B Mercuri ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Differential Diagnosis ◽  
Disease Progression ◽  
Hearing Impairment

scholarly journals Progression of Voice and Speech Impairment in the Course of Parkinson's Disease: A Longitudinal Study

2013 ◽  
Vol 2013 ◽  
pp. 1-8 ◽  
Author(s):  
S. Skodda ◽  
W. Grönheit ◽  
N. Mancinelli ◽  
U. Schlegel
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Acoustic Analysis ◽  
Motor Impairment ◽  
Time Interval ◽  
Speech Impairment ◽  
Speech Performance ◽  
The Individual ◽  
Voice And Speech

Impairment of voice and speech occurs in the majority of patients in the course of Parkinson's disease (PD). The aim of the current study was to survey the changes of voice and speech performance in the individual patients over time. 80 patients with PD and 60 healthy speakers were tested and retested after at least 12 months (average time interval: 32.5 months). Participants had to read a given text which was digitally recorded as a source for the perceptual and acoustic analysis. Stage of the disease and global motor impairment were rated according to the accepted scales. As a result, abnormalities of voice and speech were already present in mildly affected patients and there were significant deteriorations of quality of voice and articulatory velocity and precision between baseline and followup examination which showed no correlation with the time interval between the visits. Summarized, voice, and speech performance were found to further deteriorate in the individual patient in the course of time although global motor impairment was widely stable which might be a hint for nondopaminergic mechanisms of progression of dysarthrophonia. Further investigations are warranted to get a better insight into the dynamics of the progression of voice and speech impairment in PD as a precondition for the development of therapeutic approaches.

Sleep problems affect quality of life in Parkinson's disease along disease progression

2021 ◽  
Vol 81 ◽  
pp. 307-311 ◽  
Author(s):  
Claudio Liguori ◽  
Valentino De Franco ◽  
Rocco Cerroni ◽  
Matteo Spanetta ◽  
Nicola Biagio Mercuri ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Disease Progression ◽  
Sleep Problems

scholarly journals Detection of Dermal Alpha-Synuclein Deposits as a Biomarker for Parkinson’s Disease

2021 ◽  
pp. 1-11
Author(s):  
Kathrin Doppler
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Immunohistochemical Staining ◽  
Outcome Measure ◽  
Alpha Synuclein ◽  
Good Sensitivity ◽  
Promising Tool ◽  
Skin Biopsies ◽  
Methodological Problems ◽  
Sensitivity Specificity

Alpha-synuclein deposits are detectable in skin biopsies of patients with Parkinson’s disease and other synucleinopathies like multiple system atrophy by immunohistochemical staining. As they are easily to obtain, they appear a promising tool for the pre-mortem histopathological confirmation of the disease and as a potential outcome measure in studies targeting alpha-synuclein aggregates. Good sensitivity, specificity, and practicability are the most important requirements of a biomarker. The review gives an overview on all three aspects, addresses methodological problems and the lack of standardized procedures as a major problem and gives an outlook on the future of skin biopsy as a potential diagnostic tool in synucleinopathies.

Dissecting the Effects of Disease and Treatment on Impulsivity in Parkinson's Disease

2012 ◽  
Vol 18 (6) ◽  
pp. 942-951 ◽  
Author(s):  
Alison C. Simioni ◽  
Alain Dagher ◽  
Lesley K. Fellows
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Disease Progression ◽  
Risk Taking ◽  
Temporal Discounting ◽  
Baseline Risk ◽  
Neural Basis ◽  
Risky Decision ◽  
Balloon Analogue Risk Task

AbstractConverging evidence, including observations in patients with Parkinson's disease (PD), suggests that dopamine plays a role in impulsivity. This multi-faceted construct includes considerations of both time and risk; determining how these more specific processes are affected by PD and dopaminergic treatment can inform neurobiological models. We examined the effects of PD and its treatment on temporal discounting and risky decision-making in a cohort of 23 mild-moderate PD patients and 20 healthy participants. Patients completed the Balloon Analogue Risk Task and a temporal discounting paradigm both on and off their usual dopamine replacement therapy. PD patients did not differ from controls in their initial risk-taking on the Balloon Analogue Risk Task, but took progressively more risks across trials when on medication. A subset of patients and controls was tested again, 1.5–3 years later, to explore the effects of disease progression. On follow-up, baseline risk-taking diminished in patients, but the tendency to take increasing risks across trials persisted. Neither disease progression nor its treatment affected the temporal discounting rate. These findings suggest a different neural basis for temporal discounting and risk-taking, and demonstrate that risk-taking can be further decomposed into initial and trial-by-trial effects, with dopamine affecting only the latter. (JINS, 2012, 18, 1–10)

Sign in / Sign up

Export Citation Format

Share Document